OmniAb, Inc.
OmniAb, Inc., headquartered in the United States, is a leading biotechnology company specialising in the development of innovative antibody discovery platforms. Founded in 2018, OmniAb has rapidly established itself in the biopharmaceutical industry, focusing on providing unique solutions for therapeutic antibody development. The company’s core offerings include its proprietary OmniAb platform, which enables the generation of fully human antibodies with high specificity and affinity. This technology sets OmniAb apart, allowing for accelerated drug discovery processes and enhanced therapeutic efficacy. With a strong market position, OmniAb has achieved significant milestones, including strategic partnerships and collaborations that bolster its presence in major operational regions across North America and Europe. The company continues to drive advancements in antibody therapeutics, positioning itself as a key player in the evolving landscape of biomedicine.
DitchCarbon Score
How does OmniAb, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
OmniAb, Inc.'s score of 20 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
OmniAb, Inc.'s reported carbon emissions
OmniAb, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete emissions figures or defined reduction strategies, it is challenging to assess their environmental impact or progress in addressing climate change. However, the absence of data may indicate a need for enhanced transparency and commitment to sustainability practices within the biotechnology sector. As the industry increasingly prioritises climate action, OmniAb may benefit from establishing clear emissions reduction goals and reporting frameworks to align with global standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
OmniAb, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
